Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Clinical trial NCT03184558 · TERMINATED

Trial details

NCT number: NCT03184558
Sponsor: BerGenBio ASA
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Inflammatory Breast Cancer Stage IV

Start date: 2017-07-26
Primary completion: 2018-08-20
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.